Table 2 Univariate and multivariate analysis for overall training cohort survival

Age (mean ± SD)

1.03 (1.02–1.04, p <.001)

1.02 (1.01–1.02, p <.001)

Surgery (%)

Medical insurance (%)

NO

 URBMI

YES

0.48 (0.40–0.58, p <.001)

0.81 (0.67–0.97, p =.026)

 UEBMI

0.66 (0.54–0.81, p <.001)

0.70 (0.57–0.86, p =.001)

Radiotherapy (%)

Marital (%)

NO

 Married

YES

0.44 (0.35–0.56, p <.001)

 Others

1.20 (0.91–1.60, p =.203)

Chemotherapy (%)

Ethnic (%)

NO

 Han

YES

0.42 (0.33–0.54, p <.001)

0.33 (0.25–0.42, p <.001)

 Minority

0.81 (0.68–0.96, p =.017)

β2.microglobulin (%)

Pathological (%)

≤ 2.5

 Squamous carcinoma

> 2.5

2.09 (1.75–2.50, p <.001)

1.51 (1.25–1.83, p <.001)

 Adenocarcinoma

1.03 (0.78–1.37, p =.832)

1.39 (1.04–1.85, p =.028)

A/G ratio (%)

 Others

1.55 (1.03–2.34, p =.037)

2.44 (1.60–3.70, p <.001)

≤ 1.8

FIGO staging (%)

> 1.8

0.87 (0.65–1.17, p =.362)

 I

NLR (%)

 II

0.81 (0.68–0.96, p =.017)

≤ 4.5

 III

> 4.5

2.64 (2.19–3.18, p <.001)

1.65 (1.33–2.06, p <.001)

 IV

PLR (%)

HPV (%)

2.27 (1.72–2.98, p <.001)

1.80 (1.35–2.41, p <.001)

≤ 216.52

 negative

3.99 (3.06–5.20, p <.001)

3.34 (2.52–4.42, p <.001)

> 216.52

2.34 (1.96–2.80, p <.001)

1.45 (1.17–1.79, p =.001)

 Positive

12.23 (9.09–16.47, p <.001)

9.50 (6.93–13.01, p <.001)